Asymchem Laboratories (Tianjin) Co., Ltd. (HKG:6821)

Market Cap	46.01B +54.2%
Revenue (ttm)	7.42B +14.9%
Net Income	1.26B +19.4%
EPS	3.52 +17.5%
Shares Out	n/a
PE Ratio	36.50
Forward PE	28.53
Dividend	1.20 (1.22%)
Ex-Dividend Date	Jun 25, 2025

Volume	384,700
Average Volume	822,694
Open	97.50
Previous Close	98.45
Day's Range	94.45 - 98.05
52-Week Range	42.25 - 116.60
Beta	0.07
RSI	56.88
Earnings Date	Mar 30, 2026

About HKG:6821

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in ke...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 10,617
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2025, HKG:6821's revenue was 6.67 billion, an increase of 14.91% compared to the previous year's 5.80 billion. Earnings were 1.13 billion, an increase of 19.35%.

Financial numbers in CNY